share_log

4: Statement of changes in beneficial ownership of securities-Officer Tapolczay David

SEC ·  Apr 25 05:05

Summary by Futu AI

David Tapolczay, the Chief Executive Officer of Conduit Pharmaceuticals, has engaged in a transaction involving the company's stock on April 22, 2024. The specific details of the transaction, including the number of shares, nature of shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Consequently, the number of shares held by Tapolczay after the action remains unknown.
David Tapolczay, the Chief Executive Officer of Conduit Pharmaceuticals, has engaged in a transaction involving the company's stock on April 22, 2024. The specific details of the transaction, including the number of shares, nature of shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Consequently, the number of shares held by Tapolczay after the action remains unknown.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated